A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Summary

The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home. The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.

Timeline

Start

2023-04-01

Primary completion

2024-02-13

Completion

2024-02-13

Drugs

Indications